PHARMACOLOGIC REDUCTION OF ALCOHOL CONSUMPTION IN ALCOHOLIC PATIENTS

最近的研究表明，酒精消费是由 几种相互作用的神经递质，包括多巴胺和 血清素系统 在随机双盲设计中， 门诊酒精患者将接受L-DOPA或L-5-羟色氨酸， 外周脱羧酶抑制剂卡比多巴或 安慰剂治疗一年 今年以来，酒精消费... 症状，肝功能，对酒精的渴望，精神状态， 心理社会功能和药物依从性将是 定期评估。 在进入研究之前， 3个月后和1年后，将进行以下程序 用于测量药物作用：（1）行为评价;（2） 测定药物、单胺、激素和 血液和脑脊液中的肽;（3）直立性改变 心率血压和血浆去甲肾上腺素 血浆加压素反应的评估 生理盐水注射。 饮酒量的变化将与 生化和行为参数。

Recent studies indicate that alcohol consumption is regulated by several interacting neurotransmitters, including the dopamine and serotonin systems. In a randomized double-blind design, chronic alcoholic outpatients will receive L-DOPA or L-5-hydroxytryptophan, both with the peripheral decaboxylase inhibitor carbidopa or placebo for a l-year period. During this year, alcohol consump- tion, liver function, craving for alcohol, mental status, psychosocial functioning, and compliance with medication will be assessed at regular intervals. Prior to entry into the study, after 3 months, and at 1 year, the following procedures will be conducted to measure drug effects: (1) behavioral evaluation; (2) determination of concentrations of drugs, monoamines, hormones, and peptides in blood and cerebrospinal fluid; (3) orthostatic changes in heart rate, blood pressure, and plasma norepinephrine concentrations; and (4) assessment of plasma vasopressin response to saline infusion. Changes in alcohol consumption will be related to biochemical and behavioral parameters.